Overview

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis

Status:
Withdrawn
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the tolerability of treatment with human lactoferrin 1-11 peptide (hLF1-11) administered intravenously as a single dose given for 10 consecutive days, to patients with bacteremia due to staphylococcus epidermidis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AM-Pharma
Treatments:
Lactoferrin